<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223557</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SR-388</org_study_id>
    <nct_id>NCT04223557</nct_id>
  </id_info>
  <brief_title>A Cholesterol Lowering Therapy of Non-invasive Focused High-intensity Ultrasound Mediated Perirenal Fat Modification</brief_title>
  <acronym>CONCISE</acronym>
  <official_title>A Novel Serum Cholesterol Lowering Therapy of Non-invasive Focused High-intensity Ultrasound Mediated Perirenal Fat Modification：A Randomized, Sham-control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangqing Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, sham-control,pilot trial, aims to evaluate the safety and efficacy of
      the novel serum cholesterol lowering therapy of non-invasive high-intensity focused
      ultrasound mediated perirenal fat modification(PRFM).56 subjects will receive PRFM therapy
      and the other 28 subjects will receive sham control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been known that the accumulation of visceral fat is associated with dyslipidemia and
      the occurrence of arteriosclerotic cardiovascular disease(ASCVD).Peri-renal fat is a special
      type of visceral fat which is different in histology, physiology, and functions. The positon
      of peri-renal fat is more stable than other visceral fat,which might be influenced by breath
      or body position changes.Studies have found that perirenal fat is an early predictor of
      ASCVD, and its accumulation is closely related to the occurrence and development of
      ASCVD.Therefore, the reduction of visceral fat,especially peri-renal fat , has a sufficient
      scientific basis for treating dyslipidemia and reducing the occurrence of cardiovascular
      disease.

      In investigators' previous experiments, surgical ablation of bilateral perirenal adipose
      tissue led to long-term, effective reduction of serum cholesterol in high-fat diet rats and
      alleviated the cardiovascular injury,based on which,in this study the investigators provide a
      novel non-invasive therapy of high-intensity focused ultrasound mediated perirenal fat
      modification to lower the serum cholesterol and protect subjects from ASCVD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, single-blind,sham-controlled pilot study.The ratio of the treatment group versus sham-control group was 1:2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The masking range includes: study participants, most researchers (including the study leader; subjects screening researchers; case follow-up researchers; sonographers; CT scanners, members of the clinical endpoint identification committee,and etc.) except for the study statistical analysts and the therapy operators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum low-density lipoprotein cholesterol(LDL-C)</measure>
    <time_frame>3 months vs baseline</time_frame>
    <description>Changes of LDL-C at 3 months compared with baseline post-procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study</measure>
    <time_frame>3 months</time_frame>
    <description>Serious adverse events including all-cause mortality,acute renal failure, acute intestinal perforation, severe embolic events and etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol (TC)</measure>
    <time_frame>3 months</time_frame>
    <description>Changes of serum TC at 3 months compared with baseline post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum non- high-density lipoprotein cholesterol(non-HDL-C)</measure>
    <time_frame>3 months vs baseline</time_frame>
    <description>Changes of serum non-HDL-C at 3 months compared with baseline post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglyceride (TG)</measure>
    <time_frame>3 months vs baseline</time_frame>
    <description>Changes of serum TG at 3 months compared with baseline post-procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Hypercholesteremia</condition>
  <condition>Dyslipidemias</condition>
  <condition>Arteriosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In treatment group,participants will receive the whole peri-renal fat modification therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In sham control group,participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High-intensity focused ultrasound mediated perirenal fat modification</intervention_name>
    <description>High-intensity focused ultrasound(HIFU) is an externally delivered, completely noninvasive focused therapeutic ultrasound device.It is capable of focusing the resulting ultrasound beam to a small &quot;cigar&quot;-shaped volume,which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham control procedure</intervention_name>
    <description>participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.</description>
    <arm_group_label>Sham control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 40-70 years old.

          -  Each side of caudal perirenal fat volume &gt;8000mm3（measured by ultrasound）.

          -  Willing to sign the informed consent form of the study.

          -  Subjects with 3.4 ≤ LDL-C &lt; 4.9 mmol / L or 5.2 ≤ TC &lt; 7.2 mmol / L, have at least 2
             of the following risk factors:

               -  History of hypertension.

                    -  History of smoking (more than 10 years and more than 10 cigarettes per day).

                         -  Male ≥ 45 years old, female ≥ 55 years old.

                              -  HDL-C≤1 mmol/L.

        Exclusion Criteria:

          -  With familial hyperlipidemia.

          -  With cholesterol metabolism related drugs were taken (e.g. statins, fibrate
             lipid-lowering drugs, thiazide diuretics, glucocorticoid, para-amino salicylic acid,
             colchicine, thyroid hormone, thyroid preparation, hypoglycemic, heparin, new oral
             anticoagulant, chlortetracycline, kanamycin, neomycin).

          -  With cardiovascular disease(e.g. all types of atrial fibrillation; severe structural
             heart disease; Second degree or above heart block; atherosclerotic cardiovascular
             disease)

          -  With endocrine-related disease(e.g. Diabetes, Cushing syndrome, thyroid dysfunction,
             primary aldosteronism, Hypofunction of adrenal cortex, Polycystic Ovary Syndrome,
             Hyperparathyroidism, Insulin tumor, Zollinger-Ellison syndrome)

          -  With Autoimmune Diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis,
             Sjögren syndrome, scleroderma, ulcerative colitis, dermatomyositis, pemphigus, mixed
             connective tissue disease, sarcoidosis, Takayasu Arteritis)

          -  With severe hematologic diseases (e.g. leukemia, lymphoma, aplastic anemia, autoimmune
             hemolytic anemia, multiple myeloma, Primary Immune Thrombocytopenia, thrombotic
             thrombocytopenic Purpura, abnormal coagulation)

          -  With infectious disease (e.g. Hepatitis, tuberculosis, AIDS, syphilis, malaria,
             measles)

          -  With parasitic disease

          -  With significant liver dysfunction (ALT or AST elevation greater than 2 times normal
             upper limit or other evidence of liver injury)

          -  With significant renal dysfunction (GFR &amp; Lt; 90 ML / min / 1.73 m2 or other evidence
             of renal injury)

          -  With urinary calculi and/or hematuria (gross hematuria or occult blood positive).

          -  With skin infection at the waist.

          -  With malignant tumor.

          -  With pregnancy or in suckling period or planning for pregnancy in trial period.

          -  Subject is unwilling to sign an informed consent form.

          -  Subject is unable or unwilling to complete follow-up evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangqing Kong, M.D.&amp;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangqing Kong, M.D.&amp;PhD</last_name>
    <phone>+86 13951610265</phone>
    <phone_ext>+8602568217328</phone_ext>
    <email>kongxq@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Sun, M.D.&amp;PhD</last_name>
    <phone>+86 13815860536</phone>
    <phone_ext>+8602568135274</phone_ext>
    <email>shunwee@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>JiangSu Province Hospital / The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiangqing Kong, M.D.&amp;PhD</last_name>
      <phone>+8613951610265</phone>
      <phone_ext>+8602568217328</phone_ext>
      <email>kongxq@njmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiangqing Kong, M.D.&amp;PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Sun, M.D.&amp;PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huayiyang Zou, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Authors/Task Force Members:, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.</citation>
    <PMID>27594540</PMID>
  </reference>
  <reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12. Erratum in: J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3024-3025. J Am Coll Cardiol. 2015 Dec 22;66(24):2812.</citation>
    <PMID>24239923</PMID>
  </reference>
  <reference>
    <citation>Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia in Adults. Chinese guidelines for the management of dyslipidemia in adults(revised edition 2016)[J].Chinese Circulation Journal,2016,31(10):937-953.</citation>
  </reference>
  <reference>
    <citation>Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015 Mar-Apr;9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7.</citation>
    <PMID>25911072</PMID>
  </reference>
  <results_reference>
    <citation>Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013 Jan;93(1):359-404. doi: 10.1152/physrev.00033.2011. Review.</citation>
    <PMID>23303913</PMID>
  </results_reference>
  <results_reference>
    <citation>Wassink AM, van der Graaf Y, van Haeften TW, Spiering W, Soedamah-Muthu SS, Visseren FL; SMART Study Group. Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study. Diabet Med. 2011 Aug;28(8):932-40. doi: 10.1111/j.1464-5491.2011.03318.x.</citation>
    <PMID>21749443</PMID>
  </results_reference>
  <results_reference>
    <citation>Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005 Dec;330(6):280-9. Review.</citation>
    <PMID>16355012</PMID>
  </results_reference>
  <results_reference>
    <citation>Kortelainen ML, Särkioja T. Coronary atherosclerosis and myocardial hypertrophy in relation to body fat distribution in healthy women: an autopsy study on 33 violent deaths. Int J Obes Relat Metab Disord. 1997 Jan;21(1):43-9.</citation>
    <PMID>9023600</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Xiangqing Kong</investigator_full_name>
    <investigator_title>Head of Cardiology,Director,Clinical Professor,Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypercholesteremia,Dyslipidemias,ASCVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external Independent Review Panel.Requestors will be required to sign a Data Access Agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

